Care Patterns, Outcomes, and Costs in Peripheral T-Cell Lymphoma Patients with First-Line Treatment in Routine...

Area of Science:

• Oncology
• Hematology
• Real-world evidence

Background:

• Limited real-world data on care patterns for peripheral T-cell lymphoma (PTCL) patients.
• Understanding treatment variations and outcomes in European PTCL patients is crucial.

Purpose of the Study:

• To report on care patterns and outcomes in first-line PTCL treatment across France, UK, Germany, and Italy.
• To analyze real-world data on treatments, response rates, survival, and costs.

Main Methods:

• Retrospective chart review of adult PTCL patients with newly diagnosed disease.
• Inclusion criteria: ≥1 line of therapy and ≥1 year of follow-up data.
• Outcomes assessed: treatments, best response, progression-free survival (PFS), overall survival (OS), and treatment costs.

Main Results:

• 195 patients analyzed from France (53), UK (56), Germany (56), and Italy (30).
• Common first-line regimens: CHOP (49.7%) and CHOEP (36.4%). Complete response rate was 59.7%.
• Median PFS: 49.4 months; median OS: 77.1 months. First-line treatment costs highest in the UK, driven by different factors per country.

Conclusions:

• This analysis enhances understanding of treatment outcomes and costs for PTCL patients in Europe.
• Real-world data reveal significant variations in care patterns and associated costs across European countries.